The Current Status of Gene Therapy for the Treatment of Cancer

References

• Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013;525(2):162–169. doi:10.1016/j.gene.2013.03.137
   PubMed Web of Science ®Google Scholar
• Sharma AR, Kundu SK, Nam JS, et al. Next generation delivery system for proteins and genes of therapeutic purpose: why and how? Biomed Res Int. 2014;2014.
   Web of Science ®Google Scholar
• Templeton NS, editor. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. Crc Press; 2008.
   Google Scholar
• Vermezovic J, Stergiou L, Hengartner MO, Di Fagagna FD. Differential regulation of DNA damage response activation between somatic and germline cells in Caenorhabditis elegans. Cell Death Differ. 2012;19(11):1847–1855. doi:10.1038/cdd.2012.69
   Web of Science ®Google Scholar
• Reis RL. Encyclopedia of Tissue Engineering and Regenerative Medicine. Academic Press; 2019.
   Google Scholar
• Colella P, Ronzitti G, Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol Ther Methods Clin Dev. 2018;8:87–104. doi:10.1016/j.omtm.2017.11.007
   PubMed Web of Science ®Google Scholar
• Merten O-W, Charrier S, Laroudie N, et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther. 2011;22(3):343–356. doi:10.1089/hum.2010.060
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.
   PubMed Web of Science ®Google Scholar
• Sung YK, Kim SW. The practical application of gene vectors in cancer therapy. Integrat Cancer Sci Therap. 2018;5:1–5.
   Google Scholar
• Suleiman AA, Saedi WY, Muhaidi MJ. Widely used gene editing strategies in cancer treatment a systematic review. Gene Rep. 2020;100983.
   Web of Science ®Google Scholar
• Zhang HX, Zhang Y, Yin H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol Therapy. 2019;27(4):735–746. doi:10.1016/j.ymthe.2019.01.014
   Web of Science ®Google Scholar
• Ernst MP, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WP. Ready for repair? Gene editing enters the clinic for the treatment of human disease. Mol Therapy Methods Clin Dev. 2020.
   Web of Science ®Google Scholar
• Sallmyr A, Tomkinson AE. Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem. 2018;293(27):10536–10546. doi:10.1074/jbc.TM117.000375
   Web of Science ®Google Scholar
• Zaman QU, Li C, Cheng H, Hu Q. Genome editing opens a new era of genetic improvement in polyploid crops. Crop J. 2019;7(2):141–150. doi:10.1016/j.cj.2018.07.004
   Google Scholar
• Palpant NJ, Dudzinski D. Zinc finger nucleases: looking toward translation. Gene Ther. 2013;20(2):121–127. doi:10.1038/gt.2012.2
   Web of Science ®Google Scholar
• Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discovery. 2017;3(1):1–2. doi:10.1038/cddiscovery.2017.71
   Web of Science ®Google Scholar
• Sun N, Zhao H. Transcription activator‐like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioeng. 2013;110(7):1811–1821. doi:10.1002/bit.24890
   Web of Science ®Google Scholar
• Nakano C, Kitabatake Y, Takeyari S, et al. Genetic correction of induced pluripotent stem cells mediated by transcription activator-like effector nucleases targeting ALPL recovers enzyme activity and calcification in vitro. Mol Genet Metab. 2019;127(2):158–165. doi:10.1016/j.ymgme.2019.05.014
   Web of Science ®Google Scholar
• Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The biology of CRISPR-Cas: backward and forward. Cell. 2018;172(6):1239–1259.
   PubMed Web of Science ®Google Scholar
• Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie. 2015;117:119–128. doi:10.1016/j.biochi.2015.03.025
   PubMed Web of Science ®Google Scholar
• Terns RM, Terns MP. CRISPR-based technologies: prokaryotic defense weapons repurposed. Trends Genetics. 2014;30(3):111–118. doi:10.1016/j.tig.2014.01.003
   Web of Science ®Google Scholar
• Li Y, Glass Z, Huang M, Chen ZY, Xu Q. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials. 2020;234:119711. doi:10.1016/j.biomaterials.2019.119711
   Web of Science ®Google Scholar
• Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–1278. doi:10.1016/j.cell.2014.05.010
   PubMed Web of Science ®Google Scholar
• Mali S. Delivery systems for gene therapy. Indian J Hum Genet. 2013;19(1):3. doi:10.4103/0971-6866.112870
   PubMedGoogle Scholar
• Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomaterials Res. 2019;23(1):8. doi:10.1186/s40824-019-0156-z
   PubMedGoogle Scholar
• Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology. 2018;153(1):1–9. doi:10.1111/imm.12829
   PubMed Web of Science ®Google Scholar
• Bouard D, Alazard‐Dany N, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol. 2009;157(2):153–165. doi:10.1038/bjp.2008.349
   PubMed Web of Science ®Google Scholar
• Goswami R, Subramanian G, Silayeva L, et al. Gene therapy leaves a vicious cycle. Front Oncol. 2019;9:297.
   Web of Science ®Google Scholar
• Pilgrim S, Stritzker J, Schoen C, et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther. 2003;10(24):2036–2045. doi:10.1038/sj.gt.3302105
   PubMed Web of Science ®Google Scholar
• Johnson SA, Ormsby MJ, McIntosh A, Tait SW, Blyth K, Wall DM. Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori. Cancer Gene Ther. 2019;26(7):183–194. doi:10.1038/s41417-018-0039-9
   Web of Science ®Google Scholar
• Celec P, Gardlik R. Gene therapy using bacterial vectors. Front Biosci. 2017;22:81–95. doi:10.2741/4473
   Web of Science ®Google Scholar
• Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. Curr Pharm Biotechnol. 2013;14(1):46–60.
   PubMed Web of Science ®Google Scholar
• Ramamoorth M, Narvekar A. Non viral vectors in gene therapy-an overview. J Clin Diagnostic Res. 2015;9(1):GE01. doi:10.7860/JCDR/2015/10443.5394
   PubMed Web of Science ®Google Scholar
• Buck J, Grossen P, Cullis PR, Huwyler J, Witzigmann D. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery. ACS Nano. 2019;13(4):3754–3782. doi:10.1021/acsnano.8b07858
   PubMed Web of Science ®Google Scholar
• Yang R, Chen F, Guo J, Zhou D, Luan S. Recent advances in polymeric biomaterials-based gene delivery for cartilage repair. Bioactive Mater. 2020;5(4):990–1003. doi:10.1016/j.bioactmat.2020.06.004
   Web of Science ®Google Scholar
• Van Bruggen C, Hexum JK, Tan Z, Dalal RJ, Reineke TM. Nonviral gene delivery with cationic glycopolymers. Acc Chem Res. 2019;52(5):1347–1358. doi:10.1021/acs.accounts.8b00665
   PubMed Web of Science ®Google Scholar
• Darr JA, Zhang J, Makwana NM, Weng X. Continuous hydrothermal synthesis of inorganic nanoparticles: applications and future directions. Chem Rev. 2017;117(17):11125–11238. doi:10.1021/acs.chemrev.6b00417
   PubMed Web of Science ®Google Scholar
• Riley MK, Vermerris W. Recent advances in nanomaterials for gene delivery—a review. Nanomaterials. 2017;7(5):94. doi:10.3390/nano7050094
   Web of Science ®Google Scholar
• Alsaggar M, Liu D. Physical Methods for Gene Transfer. In Advances in Genetics. Vol. 89. Academic Press; 2015:1–24.
   Google Scholar
• Li X, Ruddy B, Taberner A. Characterization of needle-assisted jet injections. J Controlled Release. 2016;243:195–203. doi:10.1016/j.jconrel.2016.10.010
   PubMed Web of Science ®Google Scholar
• Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Therapy. 2007;15(12):2063–2069. doi:10.1038/sj.mt.6300314
   Web of Science ®Google Scholar
• Herrero MJ, Sendra L, Miguel A, Aliño SF. Physical Methods of Gene Delivery. In Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders. Cham: Springer; 2017:113–135.
   Google Scholar
• Du X, Wang J, Zhou Q, et al. Advanced physical techniques for gene delivery based on membrane perforation. Drug Deliv. 2018;25(1):1516–1525. doi:10.1080/10717544.2018.1480674
   PubMed Web of Science ®Google Scholar
• Smolders S, Kessels S, Smolders SM, et al. Magnetofection is superior to other chemical transfection methods in a microglial cell line. J Neurosci Methods. 2018;293:169–173. doi:10.1016/j.jneumeth.2017.09.017
   Web of Science ®Google Scholar
• Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687–702. doi:10.3892/ol.2018.8733
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29(2):464–488. doi:10.1016/j.ymthe.2020.12.007
   PubMed Web of Science ®Google Scholar
• Tristán-Manzano M, Justicia-Lirio P, Maldonado-Pérez N, Cortijo-Gutiérrez M, Benabdellah K, Martin F. Externally-controlled systems for immunotherapy: from bench to bedside. Front Immunol. 2020;11.
   Web of Science ®Google Scholar
• Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18(1):1–5. doi:10.1007/s40257-016-0238-9
   PubMed Web of Science ®Google Scholar
• Sostoa JD, Dutoit V, Migliorini D. Oncolytic viruses as a platform for the treatment of malignant brain tumors. Int J Mol Sci. 2020;21(20):7449. doi:10.3390/ijms21207449
   Web of Science ®Google Scholar
• Zhang -W-W, Li L, Li D, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther. 2018;29(2):160–179. doi:10.1089/hum.2017.218
   PubMed Web of Science ®Google Scholar
• Xia Y, Li X, Sun W. Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China. Curr Gene Ther. 2020;20(2):127–141. doi:10.2174/1566523220999200731003206
   Web of Science ®Google Scholar
• Shahryari A, Saghaeian Jazi M, Mohammadi S, Razavi Nikoo H, Nazari Z, Hosseini ES. Development and clinical translation of approved gene therapy products for genetic disorders. Front Genet. 2019;10:868. doi:10.3389/fgene.2019.00868
   PubMed Web of Science ®Google Scholar
• Russell L, Peng K-W. The emerging role of oncolytic virus therapy against cancer. Chine Clin Oncol. 2018;7(2):16. doi:10.21037/cco.2018.04.04
   Web of Science ®Google Scholar
• Osman AE, Luke JJ. The impact of the fecal microbiome on cancer immunotherapy. BioDrugs. 2019;33(1)::1–7. doi:10.1007/s40259-018-0328-8
   Web of Science ®Google Scholar
• Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II study using rexin-g tumor-targeted retrovector encoding a dominant-negative cyclin g1 inhibitor for advanced pancreatic cancer. Mol Therapy Oncolytics. 2019;12:56–67. doi:10.1016/j.omto.2018.12.005
   PubMed Web of Science ®Google Scholar
• Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 2010;10(5):819–832. doi:10.1517/14712598.2010.481666
   PubMed Web of Science ®Google Scholar
• Bb Pettitt D, Arshad Z, Smith J, Stanic T, Holländer G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Therapy. 2018;26(2):342–353. doi:10.1016/j.ymthe.2017.10.019
   Web of Science ®Google Scholar
• Oluwole OO, Davila ML. At The Bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. J Leukoc Biol. 2016;100(6):1265–1272. doi:10.1189/jlb.5BT1115-524R
   Web of Science ®Google Scholar
• Ali S, Kjeken R, Niederlaender C, et al. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. oncologist. 2020;25(2):e321. doi:10.1634/theoncologist.2019-0233
   PubMed Web of Science ®Google Scholar
• Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016;30(3):157–167. doi:10.1016/j.blre.2015.10.003
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today. 2017;53(11):597. doi:10.1358/dot.2017.53.11.2725754
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Eng J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Bouchkouj N, Kasamon YL, de Claro RA, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019;25(6):1702–1708. doi:10.1158/1078-0432.CCR-18-2743
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-cell lymphoma: practical implications for the community oncologist. Oncologist. 2020;25(1):e138. doi:10.1634/theoncologist.2019-0395
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Velardi A, et al. Allogeneic genetically modified T Cells (HSV-TK) as adjunctive treatment in haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) of adult patients with high-risk hematological malignancies: a pair-matched analysis from the acute leukemia working party of EBMT. 2016. 672.
   Google Scholar
• Hoogendoorn KH. Advanced Therapies: clinical, Non-clinical and Quality. Pharm Biotechn. 2019;357.
   Google Scholar
• Parashar D, Rajendran V, Shukla R, Sistla R. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. Eur J Pharm Sci. 2020;142:105159. doi:10.1016/j.ejps.2019.105159
   Web of Science ®Google Scholar
• Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci. 2006;97(8):689–696. doi:10.1111/j.1349-7006.2006.00234.x
   PubMed Web of Science ®Google Scholar
• Hu B, Weng Y, Xia X-H, Liang X-J, Huang Y. Clinical advances of siRNA therapeutics. J Gene Med. 2019;21(7):e3097. doi:10.1002/jgm.3097
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduction Targeted Ther. 2020;5(1):1–25.
   PubMed Web of Science ®Google Scholar
• Hossen MN, Wang L, Chinthalapally HR, et al. Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome. Sci Adv. 2017;22(1):eaba5379. doi:10.1126/sciadv.aba5379
   Web of Science ®Google Scholar
• Düzgüneş N. Origins of Suicide Gene Therapy. In Suicide Gene Therapy. New York, NY: Humana Press; 2019:1–9.
   Google Scholar
• Dey D, Evans GR. Suicide gene therapy by herpes simplex virus-1 thymidine kinase (HSV-TK). Targets Gene Therapy. 2011;65.
   Google Scholar
• Sonabend AM, Ulasov IV, Lesniak MS. Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol. 2007;11(A):79.
   PubMedGoogle Scholar
• Aučynaitė A, Rutkienė R, Tauraitė D, Meškys R, Urbonavičius J. Discovery of bacterial deaminases that convert 5-fluoroisocytosine into 5-fluorouracil. Front Microbiol. 2018;9:2375. doi:10.3389/fmicb.2018.02375
   Web of Science ®Google Scholar
• Zarogoulidis P, Darwiche K, Sakkas A, et al. Suicide gene therapy for cancer–current strategies. J Genet Syndr Gene Ther. 2013;4.
   Google Scholar
• El‐Kenawi AE, El‐Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170(4):712–729.
   PubMed Web of Science ®Google Scholar
• Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687–702.
   PubMed Web of Science ®Google Scholar
• Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020;40:107502.
   PubMed Web of Science ®Google Scholar